Survival of Patients With Vancomycin-Resistant Enterococcus faecium Bacteremia Treated With Conventional or High Doses of Daptomycin or Linezolid Is Associated With the Rate of Bacterial Clearance

被引:13
作者
Chuang, Yu-Chung [1 ,2 ]
Lin, Hsin-Yi [3 ]
Chen, Pao-Yu [2 ]
Lin, Chi-Ying [4 ]
Chen, Yee-Chun [2 ]
Wang, Jann-Tay [2 ]
Chang, Shan-Chwen [2 ]
机构
[1] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[3] Natl Chengchi Univ, Dept Econ, Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Yun Lin Branch, Dept Internal Med, Yunlin, Taiwan
关键词
bacteremia; daptomycin; linezolid; outcome; real-time polymerase chain reaction; vancomycin-resistant enterococci; REAL-TIME PCR; STAPHYLOCOCCUS-AUREUS; CLINICAL-OUTCOMES; BLOOD CULTURES; MORTALITY; DNA; INFECTIONS; MODEL; PHARMACOKINETICS; INTERMEDIATE;
D O I
10.1097/CCM.0000000000003264
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: Vancomycin-resistant enterococci are important pathogens for healthcare-associated infections. Although linezolid is bacteriostatic and daptomycin is rapidly bactericidal against vancomycin-resistant enterococci in vitro, it is not clear whether they differ in their effect on bacterial clearance in patients with vancomycin-resistant enterococci bloodstream infections. Design: Prospective observational study. Setting: Two university hospitals and research laboratory. Patients: Patients with vancomycin-resistant enterococci bloodstream infection proven by blood cultures were prospectively enrolled from January 2010 to July 2015. Interventions: Sequential blood samples were collected. Real-time quantitative polymerase chain reaction was used to monitor bacterial loads. Measurements and Main Results: One hundred eight patients with vancomycin-resistant enterococci bloodstream infection were enrolled. Quantitative polymerase chain reaction assays were performed on 465 blood isolates. We found this method to be closely correlated with colony-forming units and more sensitive than culture. Sixty-three patients (58.3%) received conventional dose daptomycin (6-9mg/kg), 15 (13.9%) received high-dose daptomycin ( 9mg/kg), and 30 (27.8%) were treated with linezolid (600mg every 12 hr) as sole agents. The initial mean bacterial load was 1.03 log(10) copies/mL and unrelated to survival. Survivors had a more rapid early bacterial clearance than nonsurvivors ( log(10) copies/mL/d; -0.16 vs 0.31; p = 0.02). Multivariable logistic regression showed that a slower early bacterial clearance independently predicted increased mortality (odds ratio, 3.21; 95% CI, 1.03-10.02; p = 0.045). Conventional dose daptomycin was associated with a significantly slower rate of bacterial clearance than high-dose daptomycin ( log(10) copies/mL/d; -0.04 vs -0.41; p < 0.001) and linezolid (-0.04 vs -0.56; p = 0.043). Conclusions: We found that survivors of vancomycin-resistant enterococci bloodstream infection had a significantly more rapid early bacterial clearance by quantitative polymerase chain reaction than nonsurvivors. High-dose daptomycin and linezolid were associated with more rapid bacterial clearance than conventional dose daptomycin. These results support recommendations that conventional dose daptomycin not be used for the treatment of patients with vancomycin-resistant enterococci bloodstream infection.
引用
收藏
页码:1634 / 1642
页数:9
相关论文
共 49 条
[41]   New developments in the diagnosis of bloodstream infections [J].
Peters, RPH ;
van Agtmael, MA ;
Danner, SA ;
Savelkoul, PHM ;
Vandenbroucke-Grauls, CMJE .
LANCET INFECTIOUS DISEASES, 2004, 4 (12) :751-760
[42]   VRE and VSE Bacteremia Outcomes in the Era of Effective VRE Therapy: A Systematic Review and Meta-analysis [J].
Prematunge, Chatura ;
MacDougall, Colin ;
Johnstone, Jennie ;
Adomako, Kwaku ;
Lam, Freda ;
Robertson, Jennifer ;
Garber, Gary .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2016, 37 (01) :26-35
[43]   In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains [J].
Rybak, MJ ;
Hershberger, E ;
Moldovan, T ;
Grucz, RG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1062-1066
[44]   In vivo pharmacodynamic activity of daptomycin [J].
Safdar, N ;
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :63-68
[45]   Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint? [J].
Shukla, Bhavarth S. ;
Shelburne, Samuel ;
Reyes, Katherine ;
Kamboj, Mini ;
Lewis, Jessica D. ;
Rincon, Sandra L. ;
Reyes, Jinnethe ;
Carvajal, Lina P. ;
Panesso, Diana ;
Sifri, Costi D. ;
Zervos, Marcus J. ;
Pamer, Eric G. ;
Tran, Truc T. ;
Adachi, Javier ;
Munita, Jose M. ;
Hasbun, Rodrigo ;
Arias, Cesar A. .
CLINICAL INFECTIOUS DISEASES, 2016, 62 (12) :1514-1520
[46]   FACTORS INVOLVED IN BLOOD CLEARANCE OF BACTERIA [J].
STAVITSKY, AB .
SCIENCE, 1951, 113 (2940) :520-522
[47]   Development of daptomycin for Gram-positive infections [J].
Tally, FP ;
DeBruin, MF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (04) :523-526
[48]   A quantitative LightCycler PCR to detect Streptococcus pneumoniae in blood and CSF [J].
van Haeften, R ;
Palladino, S ;
Kay, I ;
Keil, T ;
Heath, C ;
Waterer, GW .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 47 (02) :407-414
[49]  
Wang JL, 2009, EXPERT OPIN PHARMACO, V10, P785, DOI [10.1517/14656560902811811, 10.1517/14656560902811811 ]